4DMedical Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

4DMedical şirketinin kazançları yıllık ortalama -19.4% oranında azalırken, Healthcare Services sektörünün kazançları yıllık 13% oranında artan oldu. Gelirler yıllık ortalama 18.4% oranında artan oldu.

Anahtar bilgiler

-19.4%

Kazanç büyüme oranı

-1.6%

EPS büyüme oranı

Healthcare Services Sektör Büyümesi	42.6%
Gelir büyüme oranı	18.4%
Özkaynak getirisi	-50.7%
Net Marj	-958.3%
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Here's Why We're Watching 4DMedical's (ASX:4DX) Cash Burn Situation

Sep 21

We're Keeping An Eye On 4DMedical's (ASX:4DX) Cash Burn Rate

May 08

4DMedical Limited's (ASX:4DX) CEO Compensation Is Looking A Bit Stretched At The Moment

Oct 26

Here's Why We're Not At All Concerned With 4DMedical's (ASX:4DX) Cash Burn Situation

Jun 16

Here's Why We're Not Too Worried About 4DMedical's (ASX:4DX) Cash Burn Situation

Jun 05

Is 4DMedical Limited's (ASX:4DX) Shareholder Ownership Skewed Towards Insiders?

Feb 20

Gelir ve Gider Dağılımı

4DMedical nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

ASX:4DX Gelir, gider ve kazançlar (AUD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
30 Jun 24	4	-36	28
31 Mar 24	2	-33	26
31 Dec 23	1	-31	24
30 Sep 23	1	-31	23
30 Jun 23	1	-31	24
31 Mar 23	1	-30	22
31 Dec 22	1	-28	21
30 Sep 22	1	-26	20
30 Jun 22	1	-25	19
31 Mar 22	1	-23	17
31 Dec 21	0	-21	14
30 Sep 21	0	-21	13
30 Jun 21	0	-21	11
31 Mar 21	0	-26	11
31 Dec 20	0	-30	11
30 Sep 20	1	-26	9
30 Jun 20	1	-22	8
31 Mar 20	2	-16	6
31 Dec 19	2	-9	5
30 Sep 19	1	-8	4
30 Jun 19	1	-6	4
30 Jun 18	1	-4	3
30 Jun 17	1	-4	3
31 Dec 15	0	-1	0
31 Dec 14	0	0	0

Kaliteli Kazançlar: 4DX şu anda kârlı değil.

Büyüyen Kar Marjı: 4DX şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 4DX kârlı değildir ve zararlar son 5 yılda yılda 19.4% oranında artmıştır.

Büyüme Hızlandırma: 4DX 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: 4DX kârlı olmadığından, geçmiş yıl kazanç büyümesinin Healthcare Services sektörüyle ( 12.7% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: 4DX hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -50.73% ) sahiptir.

4DMedical Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Full year 2024 earnings: EPS and revenues miss analyst expectations

Full year 2024 earnings: EPS and revenues miss analyst expectations

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

First half 2023 earnings released: AU$0.06 loss per share (vs AU$0.04 loss in 1H 2022)

Full year 2022 earnings: Revenues miss analyst expectations

Full year 2021 earnings released: AU$0.082 loss per share (vs AU$0.15 loss in FY 2020)

Recent updates

Full year 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Share price stability

4DMedical Limited, Annual General Meeting, Nov 20, 2024

Here's Why We're Watching 4DMedical's (ASX:4DX) Cash Burn Situation

Consensus revenue estimates fall by 36%

Full year 2024 earnings: EPS and revenues miss analyst expectations

We're Keeping An Eye On 4DMedical's (ASX:4DX) Cash Burn Rate

Consensus revenue estimates fall by 20%

New minor risk - Profitability

No longer forecast to breakeven

Consensus revenue estimates decrease by 22%, EPS upgraded

4DMedical Limited has completed a Follow-on Equity Offering in the amount of AUD 35 million.

4DMedical Limited has filed a Follow-on Equity Offering in the amount of AUD 35 million.

No longer forecast to breakeven

Price target increased by 21% to AU$1.18

4DMedical Receives U.S. FDA Clearance for CT LVAS Lung Function Scanning Software

Forecast to breakeven in 2026

New major risk - Share price stability

4DMedical Limited Announces Resignation of Evonne Collier as a Non-Executive Director, Chair of the Remuneration and Nomination Committee

4DMedical Limited's (ASX:4DX) CEO Compensation Is Looking A Bit Stretched At The Moment

New minor risk - Market cap size

4DMedical Limited Announces the Appointment of Geraldine Mcginty to the Board of Directors

New minor risk - Profitability

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Forecast to breakeven in 2026

New major risk - Revenue and earnings growth

4DMedical Limited, Annual General Meeting, Nov 02, 2023

Forecast to breakeven in 2026

Here's Why We're Not At All Concerned With 4DMedical's (ASX:4DX) Cash Burn Situation

First half 2023 earnings released: AU$0.06 loss per share (vs AU$0.04 loss in 1H 2022)

Consensus revenue estimates increase by 55%

We Think 4DMedical (ASX:4DX) Needs To Drive Business Growth Carefully

4DMedical Limited Appoints Matt Tucker as Senior Vice President of Business Development and Strategy

4Dmedical Unveils XV Scanner

Price target increased to AU$1.33

4DMedical Limited Releases CT LVAS in Australia

American Medical Association Current Procedural Terminology Editorial Panel Accepts 4Dmedical's Application for the Addition of A New Category III CPT Code

Is 4DMedical (ASX:4DX) In A Good Position To Deliver On Growth Plans?

4DMedical Limited, Annual General Meeting, Nov 03, 2022

4DMedical Limited Updates Vanderblit 'Burn Pit' Trial Hits Primary Endpoint

Consensus forecasts updated

Full year 2022 earnings: Revenues miss analyst expectations

We're Hopeful That 4DMedical (ASX:4DX) Will Use Its Cash Wisely

4Dmedical Limited Announces CFO Changes

High number of new directors

4DMedical Limited Appoints John Livingston as Role of Senior Strategist and Executive Director

4DMedical Limited Announces Clinical Trial Results Presented At Top US Lung Conference

High number of new directors

Price target decreased to AU$1.50

Price target decreased to AU$1.50

4DMedical Limited Announces Executive Changes

We Think 4DMedical (ASX:4DX) Can Afford To Drive Business Growth

High number of new directors

4DMedical Limited Announces First Commercial Scans with I-MED to Commence in December

Full year 2021 earnings released: AU$0.082 loss per share (vs AU$0.15 loss in FY 2020)

Full year 2021 earnings released

4D Medical Announces Undertaking Clinical Trial At the John Hopkins School of Medicine in Baltimore, USA

4DMedical Limited Commences XV LVAS Clinical Trial at Johns Hopkins School of Medicine, US

Here's Why We're Not Too Worried About 4DMedical's (ASX:4DX) Cash Burn Situation

4DMedical Limited Commences Patient Recruitment for VQ Trial

New 90-day low: AU$1.65

First half 2021 earnings released: AU$0.05 loss per share (vs AU$0.04 loss in 1H 2020)

Is 4DMedical Limited's (ASX:4DX) Shareholder Ownership Skewed Towards Insiders?

4DMedical Limited Appoints Mr. Craige Pendleton-Browne as Chief Information Officer

New 90-day low: AU$2.07

4DMedical Limited Provides Update on Its First Clinical Pilot for XV Lung Ventilation Analysis Software

4DMedical Limited Completes First Commercial Scan in Australia

4Dmedical Limited Partners with University of Miami Health System to Establish the Functional Lung Imaging Research Program

4Dmedical Limited Receives TGA Approval for XV Lung Ventilation Analysis Software (XV LVAS)